AI Terminal

MODULE: AI_ANALYST
Interactive Q&A, Risk Assessment, Summarization
MODULE: DATA_EXTRACT
Excel Export, XBRL Parsing, Table Digitization
MODULE: PEER_COMP
Sector Benchmarking, Sentiment Analysis
SYSTEM ACCESS LOCKED
Authenticate / Register Log In

Hutchmed (China) Limited

Net Asset Value Apr 1, 2015

10503_dirs_2015-04-01_2a398cbd-9881-4167-99cf-edd73221388c.html

Net Asset Value

Open in Viewer

Opens in native device viewer

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 2232J

Hutchison China Meditech Limited

01 April 2015

Hutchison China MediTech Limited ("Chi-Med")

(AIM: HCM)

Directors' Shareholding

London: Wednesday, 1 April 2015: Chi-Med received notifications on 1 April 2015 that the following Directors have purchased ordinary shares of US$1.00 each in Chi-Med (the "Shares") as follows:-

Director Date of purchase Number of Shares purchased Purchase price Beneficial interest in Shares following purchases
Number of Shares % of total issued share capital
Simon To (Executive Director and Chairman) 30 March 2015

1 April 2015
13,000

15,000
GBP13.00

GBP13.65
69,000 0.13%
Edith Shih (Non-executive Director and Company Secretary) 30 March 2015

1 April 2015
13,000

15,000
GBP13.00

GBP13.65
48,000 0.09%

Ends

Enquiries

Chi-Med Telephone:        +852 2121 8200
Christian Hogg, CEO
Panmure Gordon (UK) Limited Telephone:        +44 20 7886 2500
Richard Gray
Andrew Potts
Citigate Dewe Rogerson Telephone:        +44 20 7638 9571
Anthony Carlisle Mobile:             +44 7973 611 888
David Dible Mobile:             +44 7967 566 919

About Chi-Med

Chi-Med is a China-based healthcare group focused on researching, developing, manufacturing and selling pharmaceuticals and health-related consumer products.  Its Drug R&D Division focuses on discovering and developing innovative therapeutics in oncology and autoimmune diseases.  Its China Healthcare Division manufactures, markets and distributes prescription and over-the-counter pharmaceuticals in China.  Its emerging Consumer Products Division focuses on organic and natural consumer products in Asia.

Chi-Med is majority owned by the multinational conglomerate Hutchison Whampoa Limited (SEHK:13).  For more information, please visit: www.chi-med.com.

This information is provided by RNS

The company news service from the London Stock Exchange

END

RDSPKDDQQBKDQQK

Talk to a Data Expert

Have a question? We'll get back to you promptly.